Related Experiment Video
Updated: Sep 20, 2026
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
[Elevated cyclosporine A trough levels in HCV positive kidney transplant recipients]
Luciano Wolffenbüttel1, Elsa Alídia Petry Gonçalves, Roberto Ceratti Manfro
1Hospital de Clínicas de Porto Alegre, Programa de Pós-Graduação em Ciências Médicas: Nefrologia - Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil.
Insights
Kidney transplant recipients with Hepatitis C virus (HCV) infection show higher Cyclosporine A (CsA) blood levels compared to uninfected patients. This suggests altered CsA pharmacokinetics in HCV-positive individuals, impacting immunosuppression management.
Area of Science:
- Nephrology
- Hepatology
- Pharmacology
Context:
- Kidney transplantation is a life-saving procedure for end-stage renal disease.
- Hepatitis C virus (HCV) infection is a common comorbidity in kidney transplant recipients.
- Cyclosporine A (CsA) is a critical immunosuppressant medication used post-transplant.
Purpose:
- To compare Cyclosporine A (CsA) trough levels in kidney transplant recipients who are positive for Hepatitis C virus (HCV+) versus a control group of HCV-negative recipients.
- To investigate potential differences in CsA pharmacokinetics between HCV+ and HCV- kidney transplant recipients.
Summary:
- This study compared CsA trough levels in 23 HCV+ kidney transplant recipients with 31 HCV- controls.
- HCV+ recipients exhibited significantly higher CsA trough levels during the first month post-transplant (551 vs. 418 ng/ml; p<0.05).
- These elevated levels were observed as early as the first week and persisted until discharge, indicating altered CsA pharmacokinetics in HCV+ patients.
Impact:
- Findings suggest that HCV infection may influence CsA metabolism or distribution in kidney transplant recipients.
- This could have implications for optimizing CsA dosing strategies to maintain therapeutic efficacy and minimize toxicity.
- Further pharmacokinetic studies are warranted to elucidate the mechanisms behind these observed differences.
Objective:
Compare the CsA trough levels of HCV+ kidney transplant recipients to a control group
Methods:
All anti-HCV positive patients that received a renal allograft between January 1992 and April 1996 were initially included as cases. Patients with diabetes mellitus, HBsAg+, who were taking medication that could modify CsA pharmacokinetics and those with elevated aminotransferases were excluded. For each anti-HCV positive index case the following transplanted anti-HCV negative patient was included as a control. Third generation ELISA was used for determination of the anti-HCV status and CsA dosages were performed by polarized fluorometry with polyclonal antibodies.
Results:
No differences in the demographic variables were found. The average CsA through levels in the first month were higher (551 +/- 280 ng/ml) in the 23 cases as compared to the 31 controls (418 +/- 228 ng/ml; p< 0.05). The differences became apparent at the end of the first week (528 +/- 275 versus 344 +/- 283 ng/ml; p<0.01) and persisted at discharge (582 +/-284 versus 457 +/- 229; p=0,08).
Conclusion:
We concluded that anti-HCV positive patients have higher blood levels of CsA for a particular dosage, than anti-HCV negative controls. Prospective studies with a more appropriate pharmacokinetic approach are needed to confirm the present findings.
Related Concept Videos
01:26Kidney Transplant II: Surgical Procedure
01:28Kidney Transplant I: Introduction
01:16Kidney Transplant III: Nursing Management
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:25Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance